125 related articles for article (PubMed ID: 37775332)
21. Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
Zhang X; Xiong Y; Xia Q; Wu F; Liu L; Zhou Y; Zeng L; Zhou C; Xia C; Jiang W; Liao D; Xiao L; Liu L; Yang H; Guan R; Li K; Wang J; Lei G; Zhang Y; Yang N
JAMA Netw Open; 2020 Mar; 3(3):e201226. PubMed ID: 32191330
[TBL] [Abstract][Full Text] [Related]
22. A bivalent cyclic RGD-siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts.
Liao L; Cen B; Li G; Wei Y; Wang Z; Huang W; He S; Yuan Y; Ji A
Drug Deliv; 2021 Dec; 28(1):1432-1442. PubMed ID: 34236267
[TBL] [Abstract][Full Text] [Related]
23. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Geng N; Ding CM; Liu ZK; Song S; Hu WX
Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
[TBL] [Abstract][Full Text] [Related]
24. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
[No Abstract] [Full Text] [Related]
25. Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
Yang G; Xu H; Yang L; Xu F; Zhang S; Yang Y; Wang Y
Lung Cancer; 2020 Sep; 147():229-236. PubMed ID: 32739743
[TBL] [Abstract][Full Text] [Related]
26. An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.
Zhang R; Jia M; Xu Y; Qian D; Wang M; Zhu M; Sun M; Chang J; Wei Q
Int J Cancer; 2018 Mar; 142(6):1218-1229. PubMed ID: 29134637
[TBL] [Abstract][Full Text] [Related]
27.
Li YQ; Zhang XY; Chen J; Yin JY; Li XP
J Cancer Res Ther; 2018; 14(4):881-886. PubMed ID: 29970670
[TBL] [Abstract][Full Text] [Related]
28. Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients.
Xin S; Zhao Y; Wang C; Huang Y; Zhuang W; Ma Y; Huang M; Xu X; Wang X; Zhang L
Pharmacogenomics J; 2020 Apr; 20(2):285-293. PubMed ID: 31664190
[TBL] [Abstract][Full Text] [Related]
29. The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.
Zhou F; Gao G; Ren S; Li X; He Y; Zhou C
PLoS One; 2013; 8(4):e61585. PubMed ID: 23620771
[TBL] [Abstract][Full Text] [Related]
30. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
Zhang D; Zhang C; Huang J; Guan Y; Guo Q
Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis.
Li Z; Liu Z; Wu Y; Li H; Sun Z; Han C; Zhang X; Zhang J
Thorac Cancer; 2021 Nov; 12(21):2838-2848. PubMed ID: 34622571
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
33. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
[TBL] [Abstract][Full Text] [Related]
34. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.
Liu Z; Ou W; Li N; Wang SY
Thorac Cancer; 2018 Oct; 9(10):1285-1290. PubMed ID: 30126078
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
Ma Y; Chen Q; Zhang Y; Xue J; Liu Q; Zhao Y; Yang Y; Huang Y; Fang W; Hou Z; Li S; Wang J; Zhang L; Zhao H
Cancer Chemother Pharmacol; 2023 Nov; 92(5):411-418. PubMed ID: 37518060
[TBL] [Abstract][Full Text] [Related]
36. The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.
Ding L; Li QJ; You KY; Jiang ZM; Yao HR
Medicine (Baltimore); 2016 May; 95(20):e3598. PubMed ID: 27196461
[TBL] [Abstract][Full Text] [Related]
37. Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors.
Zhu YT; Teng Z; Zhang YF; Li W; Guo LX; Liu YP; Qu XJ; Wang QR; Mao SY; Chen XY; Zhong DF
Drug Des Devel Ther; 2020; 14():1963-1970. PubMed ID: 32546963
[TBL] [Abstract][Full Text] [Related]
38. A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy.
Dong S; Ou W; Zhong Y; Zhu X; Cai Q; Zhang J; Ran F; Qian Y; Wang J; Hu S
Ann Transl Med; 2022 Jan; 10(2):101. PubMed ID: 35282037
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer.
Li J; Tong X; Li H
Indian J Cancer; 2020; 57(1):13-17. PubMed ID: 32129295
[TBL] [Abstract][Full Text] [Related]
40. Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer.
Jia M; Zhu M; Wang M; Sun M; Qian J; Ding F; Chang J; Wei Q
Oncotarget; 2016 May; 7(18):25291-303. PubMed ID: 26993769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
